Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYTOCHROME-P450 3A4' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 100 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Ho, PC; Saville, DJ; Wanwimolruk, S
      Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds

      JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
    2. Eadie, MJ
      Clinically significant drug interactions with agents specific for migraineattacks

      CNS DRUGS
    3. Kang, MH; Figg, WD; Ando, Y; Blagosklonny, MV; Liewehr, D; Fojo, T; Bates, SE
      The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel

      CLINICAL CANCER RESEARCH
    4. Pang, SK; Zheng, NY; Felix, CA; Scavuzzo, J; Boston, R; Blair, IA
      Simultaneous determination of etoposide and its catechol metabolite in theplasma of pediatric patients by liquid chromatography/tandem mass spectrometry

      JOURNAL OF MASS SPECTROMETRY
    5. Wienkers, LC
      Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery

      JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
    6. Li, W; Berenbaum, MR; Schuler, MA
      Molecular analysis of multiple CYP6B genes from polyphagous Papilio species

      INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY
    7. Eiselt, R; Domanski, TL; Zibat, A; Mueller, R; Presecan-Siedel, E; Hustert, E; Zanger, UM; Brockmoller, J; Klenk, HP; Meyer, UA; Khan, KK; He, YA; Halpert, JR; Wojnowski, L
      Identification and functional characterization of eight CYP3A4 protein variants

      PHARMACOGENETICS
    8. Baumhakel, M; Kasel, D; Rao-Schymanski, RA; Bocker, R; Beckurts, KT; Zaigler, M; Barthold, D; Fuhr, U
      Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    9. Xue, LL; Wang, HF; Wang, QM; Szklarz, GD; Domanski, TL; Halpert, JR; Correia, MA
      Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B-1 oxidation

      CHEMICAL RESEARCH IN TOXICOLOGY
    10. Mohri, K; Uesawa, Y
      Effects of furanocoumarin derivatives in grapefruit juice on nifedipine pharmacokinetics in rats

      PHARMACEUTICAL RESEARCH
    11. Khaliq, Y; Gallicano, K; Tisdale, C; Carignan, G; Cooper, C; McCarthy, A
      Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. Shin, JG; Kane, K; Flockhart, DA
      Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    13. Hutzler, JM; Hauer, MJ; Tracy, TS
      Dapsone activation of CYP2C9-mediated metabolism: Evidence for activation of multiple substrates and a two-site model

      DRUG METABOLISM AND DISPOSITION
    14. Ngui, JS; Chen, Q; Shou, MG; Wang, RW; Stearns, RA; Baillie, TA; Tang, W
      In vitro stimulation of warfarin metabolism by quinidine: Increases in theformation of 4 '- and 10-hydroxywarfarin

      DRUG METABOLISM AND DISPOSITION
    15. Kenworthy, KE; Clarke, SE; Andrews, J; Houston, JB
      Multisite kinetic models for CYP3A4: Simultaneous activation and inhibition of diazepam and testosterone metabolism

      DRUG METABOLISM AND DISPOSITION
    16. Schrag, ML; Wienkers, LC
      Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site

      DRUG METABOLISM AND DISPOSITION
    17. Kanazawa, S; Ohkubo, T; Sugawara, K
      The effects of grapefruit juice on the pharmacokinetics of erythromycin

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    18. Lohmann, AB; Smith, FL
      Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups

      PEDIATRIC RESEARCH
    19. Dai, D; Tang, J; Rose, R; Hodgson, E; Bienstock, RJ; Mohrenweiser, HW; Goldstein, JA
      Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    20. Boulton, DW; Arnaud, P; DeVane, CL
      Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    21. Boek-Dohalska, L; Hodek, P; Sulc, M; Stiborova, M
      alpha-naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6

      CHEMICO-BIOLOGICAL INTERACTIONS
    22. Lovett, BD; Strumberg, D; Blair, IA; Pang, SK; Burden, DA; Megonigal, MD; Rappaport, EF; Rebbeck, TR; Osheroff, N; Pommier, YG; Felix, CA
      Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints

      BIOCHEMISTRY
    23. Domanski, TL; He, YA; Khan, KK; Roussel, F; Wang, QM; Halpert, JR
      Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity

      BIOCHEMISTRY
    24. Schrag, ML; Wienkers, LC
      Covalent alteration of the CYP3A4 active site: Evidence for multiple substrate binding domains

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    25. Tachibana, S; Tanaka, M
      Simultaneous determination of testosterone metabolites in liver microsomesusing column-switching semi-microcolumn high-performance liquid chromatography

      ANALYTICAL BIOCHEMISTRY
    26. Foster, DJR; Somogyi, AA; Bochner, F
      Stereoselective quantification of methadone and its major oxidative metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, in human urine using high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    27. Sparreboom, A; Nooter, K
      Does P-glycoprotein play a role in anticancer drug pharmacokinetics?

      DRUG RESISTANCE UPDATES
    28. Royal, W
      Neurologic disease in injection drug users: therapeutic issues

      JOURNAL OF NEUROVIROLOGY
    29. Hara, H; Mitani, N; Adachi, T
      Inhibitory effect of nitric oxide on the induction of cytochrome P450 3A4 mRNA by 1,25-dihydroxyvitamin D-3 in Caco-2 cells

      FREE RADICAL RESEARCH
    30. Hamilton, SP; Nunes, EV; Janal, M; Weber, L
      The effect of sertraline on methadone plasma levels in methadone-maintenance patients

      AMERICAN JOURNAL ON ADDICTIONS
    31. Wolff, K; Rostami-Hodjegan, A; Hay, AWM; Raistrick, D; Tucker, G
      Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility

      ADDICTION
    32. Nwankwo, JO; Tahnteng, JG; Emerole, GO
      Inhibition of aflatoxin B1 genotoxicity in human liver-derived HepG2 cellsby kolaviron biflavonoids and molecular mechanisms of action

      EUROPEAN JOURNAL OF CANCER PREVENTION
    33. Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T
      Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4

      PHARMACEUTICAL RESEARCH
    34. Foster, DJR; Somogyi, AA; Dyer, KR; White, JM; Bochner, F
      Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    35. Muirhead, GJ; Wulff, MB; Fielding, A; Kleinermans, D; Buss, N
      Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    36. McLure, JA; Miners, JO; Birkett, DJ
      Nonspecific binding of drugs to human liver microsomes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    37. Libersa, CC; Brique, SA; Motte, KB; Caron, JF; Guedon-Moreau, LM; Humbert, L; Vincent, A; Devos, P; Lhermitte, MA
      Dramatic inhibition of amiodarone metabolism induced by grapefruit juice

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    38. Eap, CB; Bender, S; Gastpar, M; Fischer, W; Haarmann, C; Powell, K; Jonzier-Perey, M; Cochard, N; Baumann, P
      Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients

      THERAPEUTIC DRUG MONITORING
    39. Guo, LQ; Fukuda, K; Ohta, T; Yamazoe, Y
      Role of furanocoumarin derivatives on grapefruit juice-mediated inhibitionof human CYP3A activity

      DRUG METABOLISM AND DISPOSITION
    40. Stresser, DM; Blanchard, AP; Turner, SD; Erve, JCL; Dandeneau, AA; Miller, VP; Crespi, CL
      Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates

      DRUG METABOLISM AND DISPOSITION
    41. Schrag, ML; Wienkers, LC
      Topological alteration of the CYP3A4 active site by the divalent cation Mg2+

      DRUG METABOLISM AND DISPOSITION
    42. Ohno, M; Yamaguchi, I; Ito, T; Saiki, K; Yamamoto, I; Azuma, J
      Circadian variation of the urinary 6 beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    43. Cupp-Vickery, J; Anderson, R; Hatziris, Z
      Crystal structures of ligand complexes of P450eryF exhibiting homotropic cooperativity

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    44. Gourevitch, MN; Friedland, GH
      Interactions between methadone and medications used to treat HIV infection: A review

      MOUNT SINAI JOURNAL OF MEDICINE
    45. Chan, WK; Delucchi, AB
      Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4

      LIFE SCIENCES
    46. Yao, DG; Ding, SH; Burchell, B; Wolf, CR; Friedberg, T
      Detoxication of vinca alkaloids by human P450CYP3A4-mediated metabolism: Implications for the development of drug resistance

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    47. Fowler, SM; Riley, RJ; Pritchard, MP; Sutcliffe, MJ; Friedberg, T; Wolf, CR
      Amino acid 305 determines catalytic center accessibility in CYP3A4

      BIOCHEMISTRY
    48. Khan, KK; Halpert, JR
      Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    49. Waters, CM; Krejcie, TC; Avram, MJ
      Facilitated uptake of fentanyl, but not alfentanil, by human pulmonary endothelial cells

      ANESTHESIOLOGY
    50. Kusus, M; Stapleton, DD; Lertora, JJL; Simon, EE; Dreisbach, AW
      Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions

      AMERICAN JOURNAL OF THE MEDICAL SCIENCES
    51. Mol, J; Cornish, E; Mason, J; Koes, R
      Novel coloured flowers

      CURRENT OPINION IN BIOTECHNOLOGY
    52. Gebhardt, R; Lippert, C; Schneider, A; Doehmer, J
      Improved determination of drug metabolism by perifusion of recombinant V79cells carrying human CYP3A4

      TOXICOLOGY IN VITRO
    53. Kelly, PA; Wang, H; Napoli, KL; Kahan, BD; Strobel, HW
      Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4

      EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
    54. Tegeder, I; Lotsch, J; Geisslinger, G
      Pharmacokinetics of opioids in liver disease

      CLINICAL PHARMACOKINETICS
    55. Eagling, VA; Profit, L; Back, DJ
      Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    56. Kharasch, ED; Jubert, C; Senn, T; Bowdle, TA; Thummel, KE
      Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance

      JOURNAL OF CLINICAL PHARMACOLOGY
    57. Lin, YX; Anderson, GD; Kantor, E; Ojemann, LM; Wilensky, AJ
      Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women

      JOURNAL OF CLINICAL PHARMACOLOGY
    58. Kharasch, ED; Mautz, D; Senn, T; Lentz, G; Cox, K
      Menstrual cycle variability in midazolam pharmacokinetics

      JOURNAL OF CLINICAL PHARMACOLOGY
    59. Gelderblom, H; Verweij, E; Brouwer, E; Pillay, M; De Bruijn, P; Nooter, K; Stoter, G; Sparreboom, A
      Disposition of [G-H-3]paclitaxel and cremophor EL in a patient with severely impaired renal function

      DRUG METABOLISM AND DISPOSITION
    60. Heinig, R; Adelmann, HG; Ahr, G
      The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    61. Goodwin, B; Hodgson, E; Liddle, C
      The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module

      MOLECULAR PHARMACOLOGY
    62. Tenneze, L; Verstuyft, C; Becquemont, L; Poirier, JM; Wilkinson, GR; Funck-Brentano, C
      Assessment of CYP2D6 and CY2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    63. Ayajiki, K; Okamura, T; Fujioka, H; Imaoka, S; Funae, Y; Toda, N
      Involvement of CYP3A-derived arachidonic acid metabolite(s) in responses to endothelium-derived KC channel opening substance in monkey lingual artery

      BRITISH JOURNAL OF PHARMACOLOGY
    64. Bournique, B; Petry, M; Gonsset, G
      Usefulness of statistic experimental designs in enzymology: Example with recombinant hCYP3A4 and 1A2

      ANALYTICAL BIOCHEMISTRY
    65. Furukori, H; Kondo, T; Yasui, N; Otani, K; Tokinaga, N; Nagashima, U; Kaneko, S; Inoue, Y
      Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients

      PSYCHOPHARMACOLOGY
    66. FELIP E; MASSUTI B; CAMPS C; BENITO D; ISLA D; GONZALEZLARRIBA JL; LOPEZCABRERIZO MP; SALAMANCA O; PUERTOPICA J; MOYANO A; BASELGA J; ROSELL R
      SUPERIORITY OF SEQUENTIAL VERSUS CONCURRENT ADMINISTRATION OF PACLITAXEL WITH ETOPOSIDE IN ADVANCED NONSMALL CELL LUNG-CANCER - COMPARISON OF 2 PHASE-II TRIALS

      Clinical cancer research
    67. SACHSE R; BRENDEL E; MUCK W; ROHDE G; OCHMANN K; HORSTMANN R; KUHLMANN J
      LACK OF DRUG-DRUG INTERACTION BETWEEN CERIVASTATIN AND NIFEDIPINE

      International journal of clinical pharmacology and therapeutics
    68. Yokose, T; Doy, M; Kakiki, M; Horie, T; Matsuzaki, Y; Mukai, K
      Expression of cytochrome P450 3A4 in foveolar epithelium with intestinal metaplasia of the human stomach

      JAPANESE JOURNAL OF CANCER RESEARCH
    69. DESAI PB; DUAN JZ; ZHU YW; KOUZI S
      HUMAN LIVER MICROSOMAL METABOLISM OF PACLITAXEL AND DRUG-INTERACTIONS

      European journal of drug metabolism and pharmacokinetics
    70. THUMMEL KE; WILKINSON GR
      IN-VITRO AND IN-VIVO DRUG-INTERACTIONS INVOLVING HUMAN CYP3A

      Annual review of pharmacology and toxicology
    71. HSU A; GRANNEMAN GR; BERTZ RJ
      RITONAVIR - CLINICAL PHARMACOKINETICS AND INTERACTIONS WITH OTHER ANTI-HIV AGENTS

      Clinical pharmacokinetics
    72. Beauverie, P; Taburet, AM; Dessalles, MC; Furlan, V; Touzeau, D
      Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors

      AIDS
    73. IRIBARNE C; BERTHOU F; CARLHANT D; DREANO Y; PICART D; LOHEZIC F; RICHE C
      INHIBITION OF METHADONE AND BUPRENORPHINE N-DEALKYLATIONS BY 3 HIV-1 PROTEASE INHIBITORS

      Drug metabolism and disposition
    74. Szklarz, GD; Halpert, JR
      Molecular basis of P450 inhibition and activation - Implications for drug development and drug therapy

      DRUG METABOLISM AND DISPOSITION
    75. JANG GR; BENET LZ
      ANTIPROGESTIN-MEDIATED INACTIVATION OF CYTOCHROME-P450 3A4

      Pharmacology
    76. MUCK W; OCHMANN K; ROHDE G; UNGER S; KUHLMANN J
      INFLUENCE OF ERYTHROMYCIN PRE-TREATMENT AND CO-TREATMENT ON SINGLE-DOSE PHARMACOKINETICS OF THE HMG-COA-REDUCTASE INHIBITOR CERIVASTATIN

      European Journal of Clinical Pharmacology
    77. FELIX CA; WALKER AH; LANGE BJ; WILLIAMS TM; WINICK NJ; CHEUNG NKV; LOVETT BD; NOWELL PC; BLAIR IA; REBBECK TR
      ASSOCIATION OF CYP3A4 GENOTYPE WITH TREATMENT-RELATED LEUKEMIA

      Proceedings of the National Academy of Sciences of the United Statesof America
    78. WOLKENSTEIN P; TAN C; LECOEUR S; WECHSLER J; GARCIAMARTIN N; CHARUE D; BAGOT M; BEAUNE P
      COVALENT BINDING OF CARBAMAZEPINE REACTIVE METABOLITES TO P450 ISOFORMS PRESENT IN THE SKIN

      Chemico-biological interactions
    79. CHIBA M; NISHIME JA; CHEN IW; VASTAG KJ; SAHLY YS; KIM BM; DORSEY BD; VACCA JP; LIN JH
      METABOLITE-P450 COMPLEX-FORMATION BY METHYLENEDIOXYPHENYL HIV PROTEASE INHIBITORS IN RAT AND HUMAN LIVER-MICROSOMES

      Biochemical pharmacology
    80. KIM BR; OH HS; KIM DH
      DIFFERENTIAL INHIBITION OF AFLATOXIN B-1 OXIDATION BY GESTODENE ACTION ON HUMAN LIVER-MICROSOMES

      Biochemistry and molecular biology international
    81. SZKLARZ GD; HALPERT JR
      MOLECULAR MODELING OF CYTOCHROME-P450 3A4

      Journal of computer-aided molecular design
    82. LANG DH; RETTIE AE; BOCKER RH
      IDENTIFICATION OF ENZYMES INVOLVED IN THE METABOLISM OF ATRAZINE, TERBUTHYLAZINE, AMETRYNE, AND TERBUTRYNE IN HUMAN LIVER-MICROSOMES

      Chemical research in toxicology
    83. WIEBEL FJ; ANDERSSON TB; CASCIANO DA; DICKINS M; FISCHER V; GLATT H; HORBACH J; LANGENBACH RJ; LUYTEN W; TURCHI G; VANDEWALLE A
      GENETICALLY-ENGINEERED CELL-LINES - CHARACTERIZATION AND APPLICATIONSIN TOXICITY TESTING

      ATLA. Alternatives to laboratory animals
    84. SCHMIEDLINREN P; EDWARDS DJ; FITZSIMMONS ME; HE K; LOWN KS; WOSTER PM; RAHMAN A; THUMMEL KE; FISHER JM; HOLLENBERG PF; WATKINS PB
      MECHANISMS OF ENHANCED ORAL AVAILABILITY OF CYP3A4 SUBSTRATES BY GRAPEFRUIT CONSTITUENTS - DECREASED ENTEROCYTE CYP3A4 CONCENTRATION AND MECHANISM-BASED INACTIVATION BY FURANOCOUMARINS

      Drug metabolism and disposition
    85. JANG GR; BENET LZ
      ANTIPROGESTIN PHARMACODYNAMICS, PHARMACOKINETICS, AND METABOLISM - IMPLICATIONS FOR THEIR LONG-TERM USE

      Journal of pharmacokinetics and biopharmaceutics
    86. BOISSONNAT P; DELORGERIL M; PERROUX V; SALEN P; BATT AM; BARTHELEMY JC; BROUARD R; SERRES E; DELAYE J
      A DRUG-INTERACTION STUDY BETWEEN TICLOPIDINE AND CYCLOSPORINE IN HEART-TRANSPLANT RECIPIENTS

      European Journal of Clinical Pharmacology
    87. STRESSER DM; KUPFER D
      CATALYTIC CHARACTERISTICS OF CYP3A4 - REQUIREMENT FOR A PHENOLIC FUNCTION IN ORTHO HYDROXYLATION OF ESTRADIOL AND MONO-O-DEMETHYLATED METHOXYCHLOR

      Biochemistry
    88. KHARASCH ED; RUSSELL M; GARTON K; LENTZ G; BOWDLE TA; COX K
      ASSESSMENT OF CYTOCHROME-P450 3A4 ACTIVITY DURING THE MENSTRUAL-CYCLEUSING ALFENTANIL AS A NONINVASIVE PROBE

      Anesthesiology
    89. KHARASCH ED; RUSSELL M; MAUTZ D; THUMMEL KE; KUNZE KL; BOWDLE TA; COX K
      THE ROLE OF CYTOCHROME-P450 3A4 IN ALFENTANIL CLEARANCE - IMPLICATIONS FOR INTERINDIVIDUAL VARIABILITY IN DISPOSITION AND PERIOPERATIVE DRUG-INTERACTIONS

      Anesthesiology
    90. RELLING MV
      ARE THE MAJOR EFFECTS OF P-GLYCOPROTEIN MODULATORS DUE TO ALTERED PHARMACOKINETICS OF ANTICANCER DRUGS

      Therapeutic drug monitoring
    91. PEREZ EA; BUCKWALTER CA; REID JP
      COMBINATIONS OF PACLITAXEL AND ETOPOSIDE IN THE TREATMENT OF LUNG-CANCER

      Seminars in oncology
    92. COLEMAN MD; SMITH SN; KELLY DE; KELLY SL; SEYDEL JK
      STUDIES ON THE TOXICITY OF ANALOGS OF DAPSONE IN-VITRO USING RAT, HUMAN AND HETEROLOGOUSLY EXPRESSED METABOLIZING SYSTEMS

      Journal of Pharmacy and Pharmacology
    93. SCHNEIDER A; SCHMALIX WA; SIRUGURI V; DEGROENE EM; HORBACH GJ; KLEINGEIST B; LANG D; BOCKER R; BELLOC C; BEAUNE P; GREIM H; DOEHMER J
      STABLE EXPRESSION OF HUMAN CYTOCHROME-P450 3A4 IN CONJUNCTION WITH HUMAN NADPH-CYTOCHROME P450 OXIDOREDUCTASE IN V79 CHINESE-HAMSTER CELLS

      Archives of biochemistry and biophysics
    94. RAUSCHENBACH R; GIESCHEN H; HUSEMANN M; SALOMON B; HILDEBRAND M
      STABLE EXPRESSION OF HUMAN CYTOCHROME-P450 3A4 IN V79 CELLS AND ITS APPLICATION FOR METABOLIC PROFILING OF ERGOT DERIVATIVES

      European journal of pharmacology. Environmental toxicology and pharmacology section
    95. DEGROENE EM; SEINEN W; HORBACH GJMJ
      A NIH 3T3 CELL-LINE STABLY EXPRESSING HUMAN CYTOCHROME P450-3A4 USED IN COMBINATION WITH A LACZ' SHUTTLE VECTOR TO STUDY MUTAGENICITY/

      European journal of pharmacology. Environmental toxicology and pharmacology section
    96. LI AP; KAMINSKI DL; RASMUSSEN A
      SUBSTRATES OF HUMAN HEPATIC CYTOCHROME-P450 3A4

      Toxicology
    97. MEHMOOD Z; KELLY DE; KELLY SL
      METABOLISM OF THE HERBICIDE CHLORTOLURON BY HUMAN CYTOCHROME-P450 3A4

      Chemosphere
    98. SHET MS; FAULKNER KM; HOLMANS PL; FISHER CW; ESTABROOK RW
      THE EFFECTS OF CYTOCHROME B(5), NADPH-P450 REDUCTASE, AND LIPID ON THE RATE OF 6-BETA-HYDROXYLATION OF TESTOSTERONE AS CATALYZED BY A HUMANP450 3A4 FUSION PROTEIN

      Archives of biochemistry and biophysics
    99. WALKER D; FLINOIS JP; MONKMAN SC; BELOC C; BODDY AV; CHOLERTON S; DALY AK; LIND MJ; PEARSON ADJ; BEAUNE PH; IDLE JR
      IDENTIFICATION OF THE MAJOR HUMAN HEPATIC CYTOCHROME-P450 INVOLVED INACTIVATION AND N-DECHLOROETHYLATION OF IFOSFAMIDE

      Biochemical pharmacology
    100. GUENGERICH FP; GILLAM EMJ; OHMORI S; SANDHU P; BRIAN WR; SARI MA; IWASAKI M
      EXPRESSION OF HUMAN CYTOCHROME-P450 ENZYMES IN YEAST AND BACTERIA ANDRELEVANCE TO STUDIES ON CATALYTIC SPECIFICITY

      Toxicology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 14:37:10